Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGENNASDAQ:DERMNASDAQ:KPTINASDAQ:MOLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$1.69-0.6%$1.51$1.13▼$2.66$151.70M2.54370,115 shs99,593 shsDERMJourney Medical$6.97+0.3%$7.01$3.54▼$8.25$161.91M0.8782,299 shs89,203 shsKPTIKaryopharm Therapeutics$4.49-3.4%$5.13$3.51▼$17.25$40.18M0.2380,966 shs37,953 shsMOLNMolecular Partners$3.69+3.1%$3.89$3.36▼$12.22$144.54M1.1115,091 shs2,505 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen+4.29%+3.03%+17.24%+11.11%-9.09%DERMJourney Medical+8.93%+10.14%-0.71%+13.19%+40.97%KPTIKaryopharm Therapeutics+7.39%+6.65%+1.31%-4.12%-71.82%MOLNMolecular Partners+0.42%-4.92%-11.32%-16.40%-50.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGENCompugen1.5013 of 5 stars3.53.00.00.01.10.00.0DERMJourney Medical2.3785 of 5 stars3.62.00.00.01.91.70.6KPTIKaryopharm Therapeutics3.7647 of 5 stars3.51.00.04.60.62.50.6MOLNMolecular Partners2.3714 of 5 stars3.85.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 3.00Buy$4.00136.69% UpsideDERMJourney Medical 3.20Buy$9.8841.68% UpsideKPTIKaryopharm Therapeutics 3.00Buy$43.20862.14% UpsideMOLNMolecular Partners 3.50Strong Buy$12.00225.20% UpsideCurrent Analyst Ratings BreakdownLatest KPTI, DERM, CGEN, and MOLN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/13/2025KPTIKaryopharm TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$34.00 ➝ $33.005/13/2025KPTIKaryopharm TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.005/13/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$54.00 ➝ $42.003/27/2025DERMJourney MedicalIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$10.503/27/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$27.86M5.41N/AN/A$0.62 per share2.73DERMJourney Medical$56.13M2.89N/AN/A$0.91 per share7.66KPTIKaryopharm Therapeutics$145.24M0.27N/AN/A($22.10) per share-0.20MOLNMolecular Partners$5.65M26.37N/AN/A$3.99 per share0.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen-$14.23M-$0.16N/AN/AN/A-51.27%-24.51%-12.19%8/5/2025 (Estimated)DERMJourney Medical-$14.67M-$0.39N/AN/AN/A-14.76%-52.03%-11.28%8/11/2025 (Estimated)KPTIKaryopharm Therapeutics-$76.42M-$13.26N/AN/AN/A-43.99%N/A-35.95%8/5/2025 (Estimated)MOLNMolecular Partners-$61.39M-$1.92N/AN/AN/A-1,043.01%-42.20%-38.12%8/25/2025 (Estimated)Latest KPTI, DERM, CGEN, and MOLN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025CGENCompugen-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million5/15/2025Q1 2025MOLNMolecular Partners-$0.3855-$0.50-$0.1145-$0.50N/AN/A5/14/2025Q1 2025DERMJourney Medical-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million5/12/2025Q1 2025KPTIKaryopharm Therapeutics-$4.21-$2.77+$1.44-$2.77$35.12 million$30.02 million3/26/2025Q4 2024DERMJourney Medical-$0.22$0.08+$0.30$0.08$14.21 million$14.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/ADERMJourney MedicalN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A5.095.09DERMJourney Medical1.071.341.03KPTIKaryopharm TherapeuticsN/A1.331.28MOLNMolecular PartnersN/A15.2815.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%DERMJourney Medical7.25%KPTIKaryopharm Therapeutics66.44%MOLNMolecular Partners26.55%Insider OwnershipCompanyInsider OwnershipCGENCompugen9.50%DERMJourney Medical15.03%KPTIKaryopharm Therapeutics2.98%MOLNMolecular Partners5.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7089.24 million80.76 millionOptionableDERMJourney Medical9023.30 million19.80 millionN/AKPTIKaryopharm Therapeutics3808.64 million8.38 millionOptionableMOLNMolecular Partners18040.38 million37.98 millionNot OptionableKPTI, DERM, CGEN, and MOLN HeadlinesRecent News About These CompaniesMolecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 - MorningstarJune 24 at 9:38 PM | morningstar.comMMolecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025June 22 at 4:00 PM | globenewswire.comMolecular Partners Reports Positive Phase 1/2a Data for MP0533 in Relapsed/Refractory AML at EHA CongressJune 12, 2025 | nasdaq.comMolecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025June 11, 2025 | uk.finance.yahoo.comMolecular Partners to cut jobs, cash reach now anticipated to extend into 2028June 10, 2025 | msn.comMolecular Partners (NASDAQ:MOLN) Shares Up 2.2% - Time to Buy?June 10, 2025 | marketbeat.comMolecular Partners Announces Planned Operational Efficiencies and Extension of Cash RunwayJune 10, 2025 | globenewswire.comMolecular Partners to Present at Upcoming Investor ConferencesMay 19, 2025 | globenewswire.comMolecular Partners Reports Financial Results and Highlights from Q1 2025May 15, 2025 | finance.yahoo.comMolecular Partners presents new data on Radio-DARPin, Switch-DARPin programsApril 26, 2025 | markets.businessinsider.comMolecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025April 25, 2025 | globenewswire.comWhy Molecular Partners AG’s (MOLN) Stock Is Up 5.04%April 17, 2025 | aaii.comAMolecular Partners Announces all Board Proposals Approved at Annual General MeetingApril 16, 2025 | globenewswire.comDendi and Molecular Lab Partners Announce Strategic Partnership to Empower Labs NationwideApril 15, 2025 | tmcnet.comHedge funds owners may take dramatic actions as Molecular Partners AG's (VTX:MOLN) recent 15% drop adds to one-year lossesApril 6, 2025 | finance.yahoo.comHere's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom FisherApril 3, 2025 | zacks.comWhy Molecular Partners AG’s (MOLN) Stock Is Up 9.28%March 27, 2025 | aaii.comAMolecular Partners to hold three poster presentations at AACR 2025March 25, 2025 | globenewswire.comMolecular Partners Publishes Invitation to Annual General Meeting 2025March 25, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Molecular Partners (MOLN), United Therapeutics (UTHR) and Universal Health (UHS)March 17, 2025 | markets.businessinsider.comMolecular Partners (MOLN) Initiated with a Buy at LifeSci CapitalMarch 15, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKPTI, DERM, CGEN, and MOLN Company DescriptionsCompugen NASDAQ:CGEN$1.69 -0.01 (-0.59%) Closing price 04:00 PM EasternExtended Trading$1.72 +0.03 (+2.01%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Journey Medical NASDAQ:DERM$6.97 +0.02 (+0.29%) Closing price 04:00 PM EasternExtended Trading$6.96 -0.01 (-0.22%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Karyopharm Therapeutics NASDAQ:KPTI$4.49 -0.16 (-3.44%) Closing price 04:00 PM EasternExtended Trading$4.49 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Molecular Partners NASDAQ:MOLN$3.69 +0.11 (+3.07%) Closing price 03:47 PM EasternExtended Trading$4.11 +0.42 (+11.38%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides Palantir Stock Hits ATH, But Can the Rally Hold Without Volume? Costco at a Crossroads: Is the Next Move Higher or Lower? AST SpaceMobile's Signal Strengthens as Stock Nears Orbit Oracle Stock Boils Higher, $300 Price Target in Sight 3 Hot Trades for Insiders, But Are They Good Buys for Investors? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
